Numerous studies have shown that adding aldosterone receptor antagonists such as spironolactone and finerenone on the basis of standard treatment can reduce morbidity and mortality in HF patients (Epstein, 2021a; Epstein, 2021b). Here, NR3C2 is linked to hydrops fetalis.